content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

ImmunoCellular Therapeutics, Ltd. (IMUC)

0.05
-0.17
(-75.93%)
Sep 11, 4:00PM EDT
content_middle

ImmunoCellular Therapeutics (IMUC)., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers.

IMUC’s lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma

IMUC is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.

In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.

The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Previous Close: 
0.27
Open: 
0.27
Bid: 
0.26
Ask: 
0.29
1yr Target Price: 
5.00
Day's Range: 
0.26 - 0.27
52wk Range: 
0.05 - 0.55
Volume: 
749887
Average Daily Volume: 
1665720
Market Capitalization: 
2.22M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
41.93M
content_right

Pages